2005 in oncology

The approvals rows on treatment records: region, year and indication.

• 2005Bevacizumab approved in EU

  Metastatic colorectal cancer with fluoropyrimidine-based chemotherapy. Avastin marketing authorisation issued 12 January 2005.

• 2005Erlotinib approved in US

  Pancreatic cancer with gemcitabine

• 2005Exemestane approved in US

  Adjuvant after 2-3 years of tamoxifen

• 2005H101 oncolytic adenovirus approved in CN

  Late-stage nasopharyngeal carcinoma, with chemotherapy

• 2005Lenalidomide approved in US

  Transfusion-dependent anaemia in low-risk MDS with del(5q)

• 2005Letrozole (and other aromatase inhibitors) approved in US

  Adjuvant early breast cancer (letrozole)

• 2005Nab-paclitaxel approved in US

  Metastatic breast cancer after combination chemotherapy. FDA label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4

• 2005Nelarabine approved in US

  Relapsed or refractory T-ALL and T-LBL after at least two regimens (accelerated)

• 2005Palifermin approved in EU

  Same (Kepivance)

• 2005Palonosetron approved in EU

  Prevention of chemotherapy-induced nausea and vomiting (Aloxi)

• 2005Recombinant human endostatin approved in CN

  Advanced non-small-cell lung cancer, with vinorelbine and cisplatin

• 2005Sorafenib approved in US

  Advanced RCC

• 2005Temozolomide approved in US

  Newly diagnosed glioblastoma with radiotherapy

• 2005UroVysion Bladder Cancer Kit approved in US

  Aid to diagnosis of bladder cancer in patients with haematuria

The regulatory events on treatment records: designations, filings, decisions, label changes and withdrawals, most of them carrying a full date.

• 7 January 2005Paclitaxel / nab-paclitaxel: approval (US)

  nab-Paclitaxel (Abraxane) for metastatic breast cancer

• 27 December 2005Lenalidomide: approval (US)

  MDS del(5q)

• 28 December 2005Letrozole (and other aromatase inhibitors): approval (US)

  Letrozole adjuvant indication

The year reported on trial records, with the headline result the record gives.

• 2005EORTC 26981 / NCIC CE.3 (Stupp trial) reported

  OS 14.6 vs 12.1 months, HR 0.63.

  Glioma & glioblastomaTemozolomide
• 2005HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab) reported

  B-31/N9831 10-year OS 84% vs 75.2%, HR 0.63.

  HER2-positive breast cancerEarly HER2-positive breast cancerTrastuzumab
• 2005JBR.10 (NCIC CTG) reported

  Adjuvant vinorelbine and cisplatin prolonged disease-free and overall survival in completely resected stage IB to II disease; grade 3-4 neutropenia in 88 percent.

  Resectable stage I to III non-small-cell lung cancerVinorelbineCisplatin
• 2005Kerala oral cancer visual screening trial (Trivandrum) reported

  Oral cancer mortality rate ratio 0.66 in tobacco/alcohol users after 3 rounds; 81% reduction in users who attended all 4 rounds at 15 years.

  Head and neck squamous cell carcinomaOral cavity cancer (mouth and tongue)Buccal mucosa and gingivobuccal cancer (oral cancer in India)
• 2005PT-1 (Primary Thrombocythaemia 1) reported

  Composite of thrombosis, serious haemorrhage or vascular death more frequent with anagrelide (odds ratio 1.57); more arterial clots, bleeding and myelofibrosis on anagrelide.

  Essential thrombocythaemia (ET)Myeloproliferative neoplasms (PV, ET, myelofibrosis)Hydroxyurea (hydroxycarbamide)Anagrelide

The publication year on key paper records.

• 2005A gain-of-function mutation of JAK2 in myeloproliferative disorders

  Kralovics R, Passamonti F, Buser AS, et al. New England Journal of Medicine.

• 2005A pooled analysis of bone marrow micrometastasis in breast cancer

  Braun S, Vogl FD, Naume B, et al. New England Journal of Medicine.

• 2005Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

  Pao W, Miller VA, Politi KA, et al. PLOS Medicine.

• 2005BRAF mutation in thyroid cancer

  Xing M. Endocrine-related cancer.

• 2005Chinese medical herbs for chemotherapy side effects in colorectal cancer patients

  Taixiang W, Munro AJ, Guanjian L. The Cochrane database of systematic reviews.

• 2005Cytoplasmic nucleophosmin in acute myeloid leukaemia with a normal karyotype

  Falini B, Mecucci C, Tiacci E, et al. New England Journal of Medicine.

• 2005Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study

  Campbell PJ, Scott LM, Buck G, et al. The Lancet.

• 2005Distinct sets of genetic alterations in melanoma

  Curtin JA, Fridlyand J, Kageshita T, et al. New England Journal of Medicine.

• 2005Dynamics of chronic myeloid leukaemia

  Michor F, Hughes TP, Iwasa Y, et al. Nature.

• 2005Effect of screening on oral cancer mortality in Kerala, India

  Sankaranarayanan R, Ramadas K, Thomas G, et al. The Lancet.

• 2005EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

  Kobayashi S, Boggon TJ, Dayaram T, et al. New England Journal of Medicine.

• 2005Genes that mediate breast cancer metastasis to lung

  Minn AJ, Gupta GP, Siegel PM, et al. Nature.

• 2005Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

  Ren R. Nature Reviews Cancer.

• 2005MRC TE19/EORTC 30982: radiotherapy versus single-dose carboplatin as adjuvant treatment for stage I seminoma

  Oliver RT, Mason MD, Mead GM, et al. The Lancet.

• 2005Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with...

  Eberhard DA, Johnson BE, Amler LC, et al. Journal of Clinical Oncology.

• 2005Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

  Jain RK. Science.

• 2005Parkin 2005: Global cancer statistics, 2002

  Parkin DM, Bray F, Ferlay J, Pisani P. CA: A Cancer Journal for Clinicians.

• 2005Probability of pancreatic cancer following diabetes: a population-based study

  Chari ST, Leibson CL, Rabe KG, et al. Gastroenterology.

• 2005Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer

  Tomlins SA, Rhodes DR, Perner S, et al. Science.

• 2005Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma

  Stupp R, Mason WP, van den Bent MJ, et al. New England Journal of Medicine.

• 2005Tensional homeostasis and the malignant phenotype

  Paszek MJ, Zahir N, Johnson KR, et al. Cancer Cell.

• 2005Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

  Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. New England Journal of Medicine.

• 2005Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

  Romond EH, Perez EA, Bryant J, et al. New England Journal of Medicine.

• 2005VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche

  Kaplan RN, Riba RD, Zacharoulis S, et al. Nature.

The history entries editors wrote on cancer records: the dated turning points of each disease.

• 20051p/16q LOH predicts relapse (NWTS-5, Grundy)

  Wilms tumour (nephroblastoma)

• 2005A gene fusion is found in a common carcinoma

  Prostate cancer. Tomlins found TMPRSS2 fused to ERG or ETV1 in 23 of 29 prostate tumours, putting a growth gene under the control of the hormone the prostate lives in.

  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancerERGTMPRSS2
• 2005A second mutation in the same gene explains resistance

  Non-small-cell lung cancer. EGFR T790M is found in a patient relapsing after two years on gefitinib, and independently in progressing tumours that had not carried it before treatme...

  EGFR mutation and resistance of non-small-cell lung cancer to gefitinibAcquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainEGFR T790M
• 2005Adjuvant trastuzumab halves recurrence (HERA, B-31/N9831)

  HER2-positive breast cancer

  HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)
• 2005Carboplatin ×1 equals radiotherapy for stage I seminoma (MRC TE19)

  Testicular germ cell tumours

  Carboplatin
• 2005Curtin and Bastian: distinct genetic pattern with few mutations and many amplifications in acral melanoma

  Acral melanoma

  KIT
• 2005D842V shown to confer primary imatinib resistance

  PDGFRA D842V-mutant GIST

  Imatinib
• 2005HERA, NSABP B-31 and N9831: a year of adjuvant trastuzumab

  Early HER2-positive breast cancer

  HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)Trastuzumab
• 2005HIT-SKK'92: infants with desmoplastic medulloblastoma cured with chemotherapy and no radiotherapy

  SHH-activated medulloblastoma

  Methotrexate
• 2005Interferon alfa shown to prolong survival in a retrospective series

  Erdheim-Chester disease

  Interferon alfa-2a/2b
• 2005JAK2 V617F discovered

  Myeloproliferative neoplasms (PV, ET, myelofibrosis). Four groups report the mutation in most PV and half of ET/PMF; the first molecular marker for BCR-ABL1-negative MPN.

  JAK2
• 2005JAK2 V617F discovered

  Polycythaemia vera (PV). Four groups report the mutation in almost all PV; the first molecular marker for BCR-ABL1-negative MPN and the target for the JAK inhibitors that followed.

  JAK2JAK2 V617F
• 2005JAK2 V617F discovered in most polycythaemia vera and half of myelofibrosis

  Primary myelofibrosis

  JAK2JAK2 V617F
• 2005JAK2 V617F found in half of ET

  Essential thrombocythaemia (ET)

  JAK2 V617F
• 2005Kerala screening trial shows visual inspection cuts oral cancer deaths in high-risk people

  Oral cavity cancer (mouth and tongue)

• 2005Kerala trial: visual screening cuts oral cancer deaths in high-risk people

  Buccal mucosa and gingivobuccal cancer (oral cancer in India)

  Kerala oral cancer visual screening trial (Trivandrum)
• 2005Lenalidomide for del(5q)

  Myelodysplastic syndromes / neoplasms (MDS). Transfusion independence in two-thirds of del(5q) patients (List et al.).

  Lenalidomide
• 2005Lenalidomide produces transfusion independence in del(5q) MDS

  Lower-risk myelodysplastic syndromes

  Lenalidomide
• 2005Menin shown to be required by KMT2A fusion leukaemia

  NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia

  MeninKMT2A (MLL) rearrangement
• 2005MRC TE19: single-dose carboplatin equals radiotherapy in stage I

  Seminoma

  Carboplatin
• 2005New-onset diabetes after 50 carries a 1 percent three-year risk of pancreatic cancer

  Pancreatic ductal adenocarcinoma. Chari's Minnesota cohort of 2,122; observed-to-expected ratio 7.94.

  Probability of pancreatic cancer following diabetes: a population-based studyRun the ENDPAC score on every new diabetes diagnosis after 50 and scan the high scorers
• 2005NPM1 mutations described in a third of adult AML

  NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia

  NPM1 mutation
• 2005Nuclear beta-catenin and CTNNB1 mutations define adamantinomatous tumours

  Craniopharyngioma

• 2005PARP inhibition shown to kill BRCA-deficient cells (synthetic lethality)

  BRCA or PALB2-mutant pancreatic ductal adenocarcinoma

  PARP inhibitorsSynthetic lethality: paired dependencies
• 2005Phoenix definition: nadir plus 2 ng/mL

  Biochemical recurrence of prostate cancer

  PSA (prostate-specific antigen)
• 2005PT-1: hydroxyurea beats anagrelide

  Essential thrombocythaemia (ET). In 809 high-risk patients hydroxyurea plus aspirin gave fewer arterial clots, less bleeding and less progression to myelofibrosis than anagrelide p...

  PT-1 (Primary Thrombocythaemia 1)Hydroxyurea (hydroxycarbamide)Anagrelide
• 2005Rituximab controversy

  HIV-associated (AIDS-related) lymphomas. AMC 010 shows excess infection deaths with rituximab at very low CD4; later analyses restrict the risk to CD4 under 50.

  Rituximab
• 2005Secondary KIT mutations identified as the mechanism of imatinib resistance (Antonescu, Heinrich)

  Imatinib-resistant GIST

  KIT
• 2005SMARCB1/INI1 loss recognised

  Epithelioid sarcoma. Modena and colleagues link the tumour to SWI/SNF deficiency.

• 2005Sorafenib and sunitinib open the anti-angiogenic era

  Clear cell renal cell carcinoma

  Sunitinib
• 2005Sorafenib approved: first VEGF-pathway TKI in RCC

  Renal cell carcinoma

  Anti-angiogenic therapy
• 2005Sorafenib/sunitinib: VEGF era

  Renal cell carcinoma

• 2005Stupp regimen: temozolomide + RT

  Glioma & glioblastoma

• 2005Synthetic lethality of PARP inhibition in BRCA-deficient cells

  Ovarian cancer. Farmer and Bryant papers in Nature set up the PARP inhibitor era.

  PARPSynthetic lethality
• 2005Synthetic lethality of PARP inhibition in BRCA-deficient cells

  Platinum-sensitive ovarian cancer

  PARP inhibitorsBRCA1 / BRCA2 (HRD)
• 2005Systematic profiling of SBA begins

  Small intestine cancer (small bowel adenocarcinoma). Registry analyses show the distinct site distribution and association with Crohn's, coeliac and FAP.

• 2005Temozolomide chemoradiation becomes the glioblastoma standard

  Brain and spinal cord tumours (all types). The Stupp trial showed radiotherapy with concurrent and adjuvant temozolomide prolonged survival.

  Temozolomide

The since year on technology records: first use in humans or first approval, as the record states it.

• 2005Agent-based and multicellular simulations

  First use in humans or first approval, as the technology record states it.

• 2005Dose painting and biologically guided radiotherapy

  First use in humans or first approval, as the technology record states it.

• 2005In-room imaging for radiotherapy (cone-beam CT, ExacTrac, CT-on-rails, HyperSight)

  First use in humans or first approval, as the technology record states it.

• 2005Intraoperative fluorescence and Cerenkov imaging systems (SPY, Firefly, LumiSystem, LightPath)

  First use in humans or first approval, as the technology record states it.

• 2005Single-use bioprocessing systems

  First use in humans or first approval, as the technology record states it.

• 2005UGT1A1 genotyping before irinotecan

  First use in humans or first approval, as the technology record states it.

The founded year on company records.

• 2005European Myeloma Network founded

  Rotterdam

• 2005Founders Fund founded

  San Francisco, CA

• 2005Quantum Leap Healthcare Collaborative founded

  San Francisco, California, United States

• 2005SymBio Pharmaceuticals founded

  Tokyo

• 2005Y Combinator founded

  San Francisco, CA

The founded year on journal records.

• 2005Asia-Pacific journal of clinical oncology founded

  Wiley (Blackwell Publishing Asia)

• 2005Cancer biomarkers founded

  SAGE Publications (formerly IOS Press)

• 2005Clinical & translational oncology founded

  Springer

• 2005Clinical genitourinary cancer founded

  Elsevier

• 2005Future oncology founded

  Taylor & Francis

• 2005JCO Oncology Practice founded

  American Society of Clinical Oncology

• 2005Journal of cancer research and therapeutics founded

  Wolters Kluwer (Medknow Publications)

The selected publications each biography lists, which is a reading of that person rather than a reading of the year.

• 2005Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

  Cancer Cell

• 2005Adjuvant docetaxel for node-positive breast cancer (BCIRG 001)

  NEJM

• 2005Antiviral defense by APOBEC3 Family Proteins

  Uirusu

• 2005Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

  New England Journal of Medicine

• 2005Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

  British Journal of Haematology

• 2005Clinical features and prognostic factors of early breast cancer at a major cancer center in North India

  Indian Journal of Cancer

• 2005Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

  Annals of Oncology

• 2005Consumption of Vegetables and Fruits and Risk of Breast Cancer

  JAMA

• 2005Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

  New England Journal of Medicine

• 2005Determination of the coding and non-coding nucleotide sequences of genuine Edmonston-Zagreb master seed and current working seed lot

  Vaccine

• 2005Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial

  The Lancet

• 2005Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

  Lancet

• 2005Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomi...

  Lancet

• 2005Expression of DNA polymerase β cancer-associated variants in mouse cells results in cellular transformation

  Proceedings of the National Academy of Sciences

• 2005Galectin-1: a link between tumor hypoxia and tumor immune privilege

  JCO

• 2005Gynecologic Cancer as a “Sentinel Cancer” for Women With Hereditary Nonpolyposis Colorectal Cancer Syndrome

  Obstetrics & Gynecology

• 2005Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)

  Blood

• 2005Leukaemia stem cells and the evolution of cancer-stem-cell research

  Nature Reviews Cancer

• 2005Matrix Metalloproteinases as Therapeutic Targets in Cancer

  Current Cancer Drug Targets

• 2005MGMT gene silencing and benefit from temozolomide in glioblastoma

  NEJM

• 2005Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism

  Nature

• 2005Noise in gene expression: origins, consequences, and control

  Science

• 2005Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advance...

  International Journal of Radiation Oncology, Biology, Physics

• 2005Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative...

  JCO

• 2005Prevención de eventos cardiovasculares en hipertensos mayores de 65 años bajo el cuidado de un programa de control: Estudio de cohorte

  Anales de Medicina Interna

• 2005Proliferation Marker Ki-67 in Early Breast Cancer

  Journal of Clinical Oncology

• 2005Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

  NEJM

• 2005Role of the CDKN2A Locus in Patients With Multiple Primary Melanomas

  Journal of Clinical Oncology

• 2005Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  Nature

• 2005Structural Basis for Tumor Pyruvate Kinase M2 Allosteric Regulation and Catalysis ,

  Biochemistry

• 2005Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA

  Immunity

• 2005Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  Nature

  Alan Ashworth
• 2005The role of cardiac troponin I as a prognosticator in critically ill medical patients: a prospective observational cohort study

  Crit Care

• 2005Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer (HERA)

  NEJM